Mangrove Partners’s CONMED CNMD Stock Holding History

Mangrove Partners’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,224	Closed	-$432K	–	461
2026 Q1	$432K	Buy	+12,224	New	+$497K	0.04%	221

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Mangrove Partners's CNMD Position: Q2 2026 in Review

Mangrove Partners sold out of CONMED (CNMD) in Q2 2026, closing a stake of 12,224 shares — an estimated $432K sold.

Mangrove Partners first reported a position in CNMD in Q1 2026 and held it in 1 quarter. The position peaked at $432K in Q1 2026. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

Mangrove Partners reported no remaining CONMED position as of Q2 2026 after selling out during the quarter.
Mangrove Partners sold 12,224 CONMED shares in Q2 2026, an estimated $432K.
Mangrove Partners first reported a position in CONMED in Q1 2026 and held it in 1 quarter.
Mangrove Partners's CONMED position peaked at $432K in Q1 2026.
246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.